SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 8, 2020
KODIAK SCIENCES INC.
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction
2631 Hanover Street
Palo Alto, CA
|(Address of Principal Executive Offices)||(Zip Code)|
Registrants telephone number, including area code: (650) 281-0850
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|Common stock, par value $0.0001||KOD||The Nasdaq Stock Market LLC|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 8, 2020, Kodiak Sciences Inc. (the Company) held its 2020 Annual Meeting of Stockholders (the Annual Meeting). At the Annual Meeting, proxies representing 39,113,417 shares of the Companys common stock, or approximately 87.99% of the total shares entitled to vote, were present and voted on the following proposals, which are described in more detail in the Companys definitive proxy statement filed with the United States Securities and Exchange Commission (the SEC) on April 29, 2020:
Proposal One - Election of Class II Directors. The following nominees were each elected as a Class II director to serve until the 2023 annual meeting of stockholders or until his successor is duly elected and qualified.
Taiyin Yang, Ph.D.
Bassil I. Dahiyat, Ph.D.
Proposal Two - Ratification of the Appointment of Independent Registered Public Accounting Firm. The appointment of PricewaterhouseCoopers LLP as the Companys independent registered public accounting firm for the Companys fiscal year ending December 31, 2020 was ratified.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|KODIAK SCIENCES INC.|
|Date: June 9, 2020||By:|
Victor Perlroth, M.D.
Chief Executive Officer